TearView®
Seeing the Invisible
Our Story
A paradigm shift in eye care through TearView
Imagine being able to see the tear film in real time as it spreads across the whole eye following natural blinking. TearView allows you to do this, and its stability following a blink is immediately clear.
In less than 2 minutes of clinical time you can have certainty about the tear film thus saving valuable clinical time and giving satisfaction to the patient.
TearView does not interfere with the tear film and so other established techniques such as using fluorescein for determining corneal staining can be used after TearView with no interference to these techniques.
Seeing the natural tear film in real time is useful prior to cataract surgery where being confident about having a well spread stable tear film is critical for biometry so that the power of the replacement lens can be determined accurately.
For dry eye patients, the effects of treatment such as meibomian gland expression, tear replacement drops can be seen immediately and over longer periods of time allowing evaluation of treatment protocols.
For glaucoma patients, TearView can be used to determine if the medications are changing the dynamics of the tear film. Selecting glaucoma medications so that there is minimal interference to tear film dynamics is likely to result in better patient compliance.
How contact lenses change the spread and stability of the tear film can also be seen with TearView and this enables clinician to test different trial lenses to find those most suitable for individual clients.
TearView provides a new paradigm in assessing the tear film by providing real time video images of the dynamic functioning of the ‘invisible’ tear film, without the need to add a dye, such as fluorescein. It does this by sensing the photon emissivity of the eye’s surface.
These TearView videos now allow the clinician to observe and assess the real time functioning of the tear film over the whole surface of the eye (the white of the eye as well as the cornea) during blinking cycles. This is performed while the patient’s chin is on the slit lamp and they are having their primary triaging tests.
For the first time the clinician can now make definitive assessments whether a tear film function is normal or defective at this early stage in their patient assessment, and share this video data with the patient.
Our Australian company – Beyond 700 – was formed in Sydney in 2017 with the support of New South Wales government grant funding, allowing the development and now production of the innovative TearView device.
TearView was a revelation for me. From my perspective, I now don’t need more than a TearView exam combined with a slit lamp assessment for a comprehensive dry eye diagnosis.